IL-4 inhibits P-glycoprotein in normal and malignant NK cells

Human Immunology

Volumn 59, Issue 8, 1998, Pages 483-487

  Tambur, Anat R ^a   Markham, Penelope N ^a,b   Gebel, Howard M ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GLYCOPROTEIN P; RECOMBINANT INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 4; RHODAMINE 123;

ADULT; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEUKEMIA; LYMPHOCYTE; MULTIDRUG RESISTANCE; NATURAL KILLER CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

CELL LINE; FEMALE; FLOW CYTOMETRY; HUMANS; INTERLEUKIN-4; KILLER CELLS, NATURAL; LEUKEMIA; MIDDLE AGED; P-GLYCOPROTEIN; RECOMBINANT PROTEINS;

EID: 0031879970     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0198-8859(98)00042-1     Document Type: Article

References (38)

1. Stickney DR, Foon KA: Biologic response modifiers: therapeutic approaches to lymphoproliferative diseases. Curr Opin Oncol. 4(5):847, 1992.
2. Chen PL, Chen YM, Bookstein R, Lee WH: Genetic mechanisms to tumor suppression by the human p53 gene. Science 250(4987): 1576, 1990.
3. Qazilbash MH, Xiao X, Seth P, Cowan KH, Walsh CE: Cancer gene therapy using a noval adeno-associated virus vector expressing human wild-type p53. Gene Ther 4(7): 675, 1997.
4. Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B: A model for p53-induced apoptosis. Nature 389(6648): 300, 1997.
5. Reed JC: Regukation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol 7(6): 541, 1995.
6. Haldar S, Jena N, Croce CM: Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA 92(10):4507, 1995.
7. Haldae S, Chintapalli J, Croce CM: Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 56(6): 1253, 1996.
8. Cromme FV, Airey J, Heemels MT, Ploegh HL, Keating PJ, Stern PL, Meijer CJ, Walboomers JM: Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinoma. J Exp Med 179(1):335, 1994.
9. Seliger B, Hohne A, Knuth A, Bernhard H, Meyer T, Tampe R, Momburg F, Huber C: Analysis of the major histocopatibility complex class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression. Cancer Res 56(8):1756, 1996.
10. Seliger B, Hohne A, Jung D, Kallfelz M, Knuth A, Jaeger E, Bernhard H, Momburg F, Tampe R, Huber C: Expression and function of the peptide transporters in escape variants of human renal cell carcinomas. Exp Hematol 25(7):608, 1997.
11. Chin KV, Pastan I, Gottesman MM: Function and regulation of the human multidrug resistance gene. [Review]. Adv Cancer Res 60:157, 1993.
12. Borst P, Schinkel AH, Smit JJ, Wagenaar E, van Deemter L, Smith AJ, Eijdems EW, Baas F, Zaman GJ: Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals. [Review]. Pharmacol Ther 60:289, 1993.
13. Endicott JA, Ling V: The biochemistry of P-glycoprotein-mediated multidrug resistance. [Review]. Annu Rev Biochem 58:137, 1989.
14. Chaudhary PM, Roninson IB: Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 66:85, 1991.
15. Sun T, Brody J, Susin M, Marino J, Teichberg S, Koduru P, Hall WW, Urmacher C, Hajdu SI: Aggressive natural likker cell lymphoma/leukemia. A recently resognized clinicopathologic entity. AmJ Surg Pathol 17(12):1289, 1993.
16. Ohnuma K, Toyoda Y, Nishihira H, Iguchi A, Honda K, Nagao T, Kigasawa H, Tanaka Y, Kikuta H: Aggressive natural killer (NK) cell lymphoma: report of a pediatric case and review of the litrature. Leuk Lymphoma 25(3-4):387, 1997.
17. Chaudhary PM, Meschetener EB, Roninson IB: Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 80: 2735, 1992.
18. Coon JS, Wang Y, Bines SD, Markham PN, Chong ASF, Gebel HM: Multidrug resistance activity in human lymphocytes. Hum Imm 32:134, 1991.
19. Klimecki WT, Futscher BW, Grogan TM, Dalton WS: P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 80:2729, 1994.
20. Markham PN, Coon JS, Chong ASF, Gebel HM: Natural killer cell cytotoxicity and the multidrug resistance gene. Trans Proc 25:96, 1993.
21. Drenou B, Lamy T, Amiot L, Fardel O, Caulet-Maugendre S, Sasportes M, Diebold J, Le Prise PY, Fauchet R: CD3- CD56+ non-Hodgkin's lymphomas with an aggressive behavior related to multidrug resistance. Blood 89:2966, 1997.
22. Mickisch GH, Pai LH, Gottesman MM, Pastan I: Monoclonal antibody MRK16 reverses the multidrug resistance of multidrug-resistant transgenic mice. Cancer Res 52: 4427, 1992.
23. Leist M, Gantner F, Bohliger I, Germann PG, Tiegs G, Wendel A: Murin hepatocyte apoptosis induced in vitro and in vivo by TNF-α requires transcriptional arrest. J Immunol 153:1778, 1994.
24. Mechetner EB, Roninson IB: Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody. Proc Natl Acad Sci USA 89:5824, 1992.
25. Ford JM: Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitizers. Eur J Cancer 32A:991, 1996.
26. Bouffard DY, Ohkawa T, Kijima H, Irie A, Suzuki T, Curcio LD, Holm PS, Sassani A, Scanlon KJ: Oligonucleotide modulation of multidrug resistance. Eur J Cancer 32A:1010, 1996.
27. Muller C, Bailly JD, Jaffrezou JP, Goubin F, Laurent G: Pharmacological control of P-glycoprotein expression. Bull Cancer 81(5):386, 1994.
28. Verstovsek S, Maccubbin D, Ehrke MJ, Mihich E. Tumoricidal activation of murine resident peritoneal macrophages by interleukin 2 and tumor necrosis factor alpha. Cancer Res 52(14):3880, 1992.
29. Karray S, DeFrance T, Merle-berle H, Banchereau J, Debre P, Galanaud P: Interleukin 4 counteracts the IL-2 induced proliferation of monoclonal B cells. J Exp Med 168:85, 1998.
30. Taylor CW, Grogan TM, Salmon SE: Effects of interleukin-4 on the in vitro growth of human lymphoid and plasma cell neoplasms. Blood 75:1114, 1990.
31. Hoon DS, Okun E, Banez M, Irie RF, Morton DL: Interleukin 4 alone and with γ-interferon or tumor necrosis factor inhibits cell growth and modulates cell surface antigens on human renal cell carcinoma. Cancer Res 51: 5687, 1991.
32. Hoon DS, Banez M, Okun E, Morton DL, Irie RF: Modulation of human melanoma cells by interleukin-4 and in combination with γ-interferon or α-tumor necrosis factor. Cancer Res 51:2002, 1991.
33. Lotze MT: In vivo administration of recombinant human interleukin 4 to patients with cancer. J Cell Biochem 33 (Suppl F), 1991.
34. Markowitz A, Kleinerman E, Hudson M: Phase I study of recombinant IL-4 in patients with advanced cancer. Blood 74(Suppl): 146a, 1989.
35. Netaji B, Murphy S, Budd GT: Phase IA/IB trial of rIL-2 and rhuIL-4 in refractory malignancy. Proc Am Assoc Cancer Res 32:1152, 1991.
36. Maher D, Boyd A, McKendrick J: rapid response of B cell malignancies induced by interleukin 4. Blood 76 (Suppl): 152a, 1990.
37. Sosman JA, Fisher SG, Kefer C, Fisher RI, Ellis TM: A phase I trial of continuous infusion interleukin-4 (IL-4) alone and following interleukin-2 (IL-2) in cancer patients. Ann Oncol 5(5):447, 1994.
38. Freimann J, Estrov Z, Itoh K: Phase I studies of recombinant interleukin-4 in patients with hematologic malignancies. Blood 76 (Suppl):93a, 1990.